Skip to main content

Pinealon: Benefits, side effects, dosage details, and how it works

We examine what this synthetic peptide can do for cognitive function, neuroprotection, and other health concerns.

by
Last updated: Aug 15th, 2025
Pinealon Peptide Upperr

Photo by Innerbody Research

Many adults fear aging because of potential health concerns such as neurodegeneration and cognitive decline. Although one can take preventive measures to lower their risk for unfortunate age-related changes, such disorders and dysfunctions are unpredictable in their onset.

There’s a drug therapy, however, that may help smooth over the bumps in the aging process. It’s called Pinealon, a synthetic peptide with clinical uses for neuroprotection, cognitive enhancement, longevity, and other issues related to growing older. In this guide, we examine not only how Pinealon works to achieve outcomes in these areas but also its safety profile, protocol, and other factors to steer you toward the right health decision.

Jump to

Jump to:

Why you should trust us

Over the past two decades, Innerbody Research has helped tens of millions of readers make more informed decisions about staying healthy and living healthier lifestyles.

To date, our team has spent more than 1,000 cumulative hours researching and writing about therapeutic peptides. In that time, we’ve studied hundreds of scientific sources, consulted with licensed peptide prescribers, spoken with peptide users, and even tried peptides ourselves. So this guide to Pinealon rests on an enormous foundation of theoretical and practical knowledge, allowing us to give you the most illuminating spotlight on the subject that’s currently possible.

Additionally, like all health-related content on this website, this guide was thoroughly vetted by one or more members of our Medical Review Board for accuracy and will continue to be monitored for updates by our editorial team.

What is Pinealon?

Pinealon is a synthetic tripeptide consisting of the amino acid sequence glutamic acid, aspartic acid, and arginine. It’s also known as EDR peptide.

Pinealon belongs to a class of drugs called peptide bioregulators, or biochemical compounds that come from naturally occurring organisms. In Pinealon’s case, the compound comes from a nootropic and neuroprotective polypeptide complex called Cortexin, whose neuropeptide fractions are derived from the brains of cows and pigs. Pinealon’s simpler, ultra-short structure may imbue it with higher stability, better tissue penetration, and a lower risk of hazardous immune responses than its more intricate polypeptide predecessor.

Research suggests that Pinealon’s mechanism of action involves activating the gene expression and the synthesis of proteins associated with neuronal activity, as well as decreasing the intensity of neuronal cell death. More specifically, Pinealon is believed to enter cells and interact with DNA sequences, thereby influencing the activities of several key factors related to cellular and bodily processes. These include:

  • MAPK/ERK signaling pathway: The MAPK/EKR signaling pathway is important for cell proliferation, cell differentiation, and the elimination of damaged cells, among other things.
  • Proapoptotic proteins: Proapoptotic proteins help trigger apoptosis, or programmed cell death, which is critical for removing damaged or unwanted cells (e.g., cancer cells). Examples of proapoptotic proteins activated by Pinealon are caspase-3 (which is also crucial to brain development) and p53 (which has a tumor-suppressing action as well).
  • Antioxidant proteins: Antioxidant proteins play a critical defensive role against free radicals and reactive oxygen species, the proliferation of which can lead to dysregulated apoptosis, which in turn is associated with pathologies such as autoimmune diseases, cancer, and neurodegeneration.

In addition to the above, Pinealon appears to extend cellular lifespans via telomere lengthening. As we discussed in our epitalon guide, telomeres are protective “caps” of DNA sequences at the ends of chromosomes. They shorten every time a cell divides and eventually reach the point at which proper cell division is no longer possible, resulting in cellular senescence. Senescent cells, in turn, can lead to various age-related diseases, including but not limited to cancer, atherosclerosis, osteoarthritis, and cognitive decline.

Pinealon can prevent cellular senescence by regulating the production of a hormone called irisin, high levels of which are associated with longer telomere lengths and, therefore, longer cellular lifespans.

Current therapeutic uses of Pinealon

Pinealon’s relationship to DNA sequences and irisin is the basis for its main therapeutic applications: improved cognitive function, neuroprotection, and antiaging.

Below, we summarize the research in support of its use in these areas:

Improved cognitive function

Animal studies make up the bulk of research on Pinealon’s effects on cognitive function. In one such study, researchers conducted an experiment in which pregnant rats given Pinealon gave birth to offspring with improved learning ability. In a second study, considering the psychophysiological similarities between humans and monkeys, the researchers subjected two macaques to a ten-day course of Pinealon, after which the subjects exhibited significant reductions in learning time and motor reactions when identifying informational signs in visual stimuli. And in still yet another study, Pinealon was found to have a “greater positive effect” on learning than its antecedent, Cortexin, in animals navigating a maze, an effect that the researchers attributed to Pinealon’s actions on the caspase-3 system.

Neuroprotection

Human and animal studies alike have successfully demonstrated Pinealon’s utility as a neuroprotective agent. These include a trial involving 72 people with traumatic brain injury who exhibited improved memory and cognitive performance after Pinealon administration; another trial in which the peptide helped improve working memory in 59.4% of subjects; and an in vitro study involving rats with Huntington’s disease in which Pinealon appeared to restore dendritic spines, which (to quote one review) are “key structures in the regulation of neural activity.” The researchers behind a 2021 study pointed to such research to highlight Pinealon’s potential use as a treatment for Alzheimer’s disease, as the peptide appears capable of “[regulating] the expression of genes involved in [its] pathogenesis.”

Antiaging

Pinealon may help slow the aging process in a couple of ways. One is through its antioxidant activity. In a 2011 study, the peptide was found not only to restrict cellular accumulation of reactive oxygen species but also to decrease necrotic cell death, both of which are factors that may influence a person’s lifespan. Indeed, other research has shown that high levels of oxidative markers correlate with Alzheimer’s-related cognitive decline, so the less oxidative stress, the better.

Another way that Pinealon might promote longevity is via protein binding sites. Specifically, the nuclear receptor proteins PPAR-alpha and PPAR-gamma have binding sites for Pinealon, allowing the peptide to regulate their synthesis. These proteins happen to play a key role in preventing Alzheimer’s pathogenesis, as they can downregulate the enzyme responsible for the development of amyloid beta plaques (a key feature of Alzheimer’s disease).

Smaller bodies of research suggest that Pinealon may have other uses as well. For example, a 2012 study in old rats found that Pinealon injection could improve behavioral sleep, and a 2014 in vitro study in brain cortex cells demonstrated that the peptide may stimulate the expression of serotonin, a neurotransmitter that regulates mood.

Is Pinealon safe?

There are few to no dedicated safety studies on Pinealon — not in the English language, at least — but the existing relevant research points to a generally small side effect profile for peptide bioregulators in general. By way of a more specific example, we can look to studies on Cortexin (the complex from which Pinealon is derived), which is described in a 2014 study as having “high efficacy and safety.”

That’s not to say that adverse events aren’t possible. Some people may experience allergic reactions to Pinealon, or really any peptide, and by virtue of its being an injectable peptide, it may cause milder but fairly common side effects such as injection site reactions, muscle aches, gastrointestinal discomfort, headache, fatigue, lightheadness, flushing, and possibly fever.

Research-grade vs. pharmaceutical-grade Pinealon

Pinealon is not an FDA-approved medication, so you may find its clinical availability to be quite limited and then be tempted to seek it out from an online retailer. That’s a potentially treacherous path to tread, as many online retailers not only lack verified reputations but also deal in research-grade peptides.

The difference between research-grade and pharmaceutical-grade peptides comes down to purity and fitness for human consumption. Because research-grade peptides aren’t held to the same quality standards as their pharmaceutical-grade counterparts, they’re often of a dangerously low purity that increases the risk of adverse events. Hence, they are for laboratory use only and are not suitable for human consumption. If you want to have your peptide and benefit from it too, you should either stick to a prescription from a licensed physician or carefully read the fine print on the product page to ensure you’re getting pharmaceutical-grade material.

Admittedly, getting a Pinealon prescription may be difficult, but it isn’t impossible. If your physician determines that it’s necessary to treat an indicated health condition, and no other treatment is viable for you, then you could be exempted from rules that prohibit the use of non-FDA-approved medications.

What’s it like to use Pinealon?

Expectations and user experiences aren’t normally among the available information about a therapeutic peptide. Fortunately, the medical providers we’ve consulted, who are licensed prescribers of peptides, have given us invaluable insight into these otherwise esoteric factors. Thus, we’re able to summarize the key points about Pinealon’s dosing, administration, storage, and timeline of benefits below.

Dosing, administration, and storage of Pinealon

A standard Pinealon dose is 1mg, though your exact dosage may depend on individual factors such as age and weight. Your prescribing physician will likely instruct you to take five doses per week, with administration in the morning or early afternoon to optimize use of the peptide’s cognitive-enhancing effects.

Pinealon is normally administered via subcutaneous injection into the belly, thigh, or arm. Like other injectable peptides, it will likely come packaged as a powder in a vial along with needle syringes and a vial of bacteriostatic water. Before you can dose the peptide, you must reconstitute the powder into an injectable solution, which entails combining a specific measure of the water with the powder. Take your time here so that all of the powder gets dissolved. Be gentle and don’t shake the mixture, as agitation can cause degradation.

Once reconstituted, the supply of Pinealon should last four weeks. Between doses, you should store the peptide at around 4°C, or 39°F. A refrigerator, then, would be the ideal storage container.

Timeline of benefits from Pinealon

Within 1-2 weeks of beginning your Pinealon treatment, you should see an increase in your focus and mental clarity — less brain fog and more cognitive vigor — as well as improvements in mood and stress resilience.

In 4-6 weeks, the cognition- and mood-enhancing effects become more pronounced, with significantly improved memory recall and emotional balance. During this time, you may notice attendant decreases in chronic fatigue. These benefits improve further at up to 8-12 weeks.

Thereafter, Pinealon begins to yield its less outwardly noticeable (but no less important) health effects, namely the ability to reduce the risk and effects of age-related cognitive decline.

Who is a candidate for Pinealon?

Pinealon’s various therapeutic properties make it a suitable peptide therapy for the following populations:

  • Older adults: Pinealon’s neuroprotective action may help stave off forms of age-related cognitive decline, including those related to a neurodegenerative disease. Additionally, its antioxidant and telomere-preserving potential can slow aspects of the aging process and improve one’s quality of life as they do age.
  • Other people with cognitive needs: Anyone whose occupation requires long periods of focus could benefit from Pinealon’s nootropic effects. That’s a broad potential user base that includes students, creatives, office employees, and trade workers.
  • People with mood disorders: With its ability to regulate neurotransmitters, Pinealon may help people with generalized anxiety, depressive symptoms, or other symptoms of a mood disorder.
  • People with sleep disorders: The same regulatory action on neurotransmitters means that Pinealon could potentially help normalize a person’s sleep-wake cycle and thereby improve their sleep quality.

Who is not a candidate for Pinealon?

As for people who should not take Pinealon, the list includes:

  • Pregnant or breastfeeding mothers: Like many other drug treatments, Pinealon lacks sufficient scientific evidence to support its safety for the developing fetus or child.
  • People with active cancer or a history of cancer: Pinealon’s action on proapoptotic cells is, paradoxically, both anti- and procarcinogenic. It can lead to cancer when the apoptotic process doesn’t work correctly. Indeed, in a 2019 study published in the International Journal of Cancer, the researchers noted that the proapoptotic caspase-3 can potentially promote tumor formation while preventing cancer cell development.

Where to find Pinealon

Because Pinealon is not an FDA-approved substance, its availability in the United States is relatively scarce. As we suggested earlier, some licensed physicians are willing to prescribe it, but you may first need to demonstrate that Pinealon meets a health need that other, approved medications do not.

No doubt that you can also find Pinealon online, but you’ll come across many research-grade products that (again) are not suitable for human use. Perhaps there are some online retailers that sell pharmaceutical-grade products, but you have to read the fine print carefully to make sure you’re getting legitimate medication.

That said, pharmaceutical peptides belong to an ever-shifting medical landscape, and the regulations concerning Pinealon may eventually become more permissible. We’ll closely monitor the peptide space in the meantime and update this guide accordingly.

39

Sources

Innerbody uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

  1. WorldHealth Staff. (2024). Young adults are more afraid of aging than older adults. WorldHealth.

  2. Cleveland Clinic. (2023). Neurodegenerative diseases. Cleveland Clinic.

  3. Kurkin, D. V., et al. (2021). Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. PLoS ONE, 16(7), e0254493.

  4. Stocum, L. (2021). Peptides and their many uses. Dermatology Times.

  5. Khavinson, V., et al. (2020). EDR peptide: Possible mechanism of gene expression and protein synthesis regulation involved in the pathogenesis of Alzheimer’s disease. Molecules, 26(1), 159.

  6. Zhang, W., & Liu, H. T. (2002). MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Research, 12(1), 9-18.

  7. Porter, A. G., & Jänicke, R. U. (1999). Emerging roles of caspase-3 in apoptosis. Cell Death and Differentiation, 6(2), 99-104.

  8. Ozaki, T., & Nakagawara, A. (2011). Role of p53 in cell death and human cancers. Cancers, 3(1), 994-1013.

  9. Xu, X., Lai, Y., & Hua, C. (2019). Apoptosis and apoptotic body: Disease message and therapeutic target potentials. Bioscience Reports, 39(1), BSR20180992.

  10. Azad, N., & Iyer, A. K. V. (2014). Reactive oxygen species and apoptosis. In: Laher, I. (Eds.), Systems Biology of Free Radicals and Antioxidants.

  11. Kannan, K., & Jain, S. K. (2000). Oxidative stress and apoptosis. Pathophysiology, 7(3), 153-163.

  12. Shammas, M. A. (2011). Telomeres, lifestyle, cancer, and aging. Current Opinion in Clinical Nutrition and Metabolic Care, 14(1), 28-34.

  13. Childs, B. G., et al. (2017). Senescent cells: An emerging target for diseases of ageing. Nature Reviews Drug Discovery, 16, 718-735.

  14. Budamagunta, V., et al. (2023). Effect of peripheral cellular senescence on brain aging and cognitive decline. Aging Cell, 22(5), e13817.

  15. Khavinson, V. K., et al. (2016). Short peptides and telomere length regulator hormone irisin. Bulletin of Experimental Biology and Medicine, 160(3), 347-349.

  16. Rana, K. S., et al. (2014). Plasma irisin levels predict telomere length in healthy adults. Age, 36(2), 995-1001.

  17. Arutjunyan, A., et al. (2012). Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. International Journal of Clinical and Experimental Medicine, 5(2), 179-185.

  18. Georgievna, K. T., et al. (2019). The effect of the tripeptide Pinealon on the rehabilitation of cognitive functions during aging in rhesus macaques. Moscow University Anthropology Bulletin, 23.

  19. Mendzheritskii, A. M., et al. (2014). Effect of peptide geroprotectors on navigation learning in rats of different ages and caspase-3 systems in their brain structures. Advances in Gerontology, 4, 37-41.

  20. Khavinson, V., et al. (2021). Neuroprotective effects of tripeptides — epigenetic regulators in mouse model of Alzheimer’s disease. Pharmaceuticals, 14(6), 515.

  21. Khavinson, V., et al. (2017). Neuroprotective effect of EDR peptide in mouse model of Huntington's disease. Journal of Neurology and Neuroscience, 8(1), 166.

  22. García-López, P., García-Marín, V., & Freire, M. (2011). Dendritic spines and development: towards a unifying model of spinogenesis — a present-day review of Cajal's histological slides and drawings. Neural Plasticity, 2010, 769207.

  23. Khavinson, V., et al. (2011). Pinealon Increases Cell Viability by Suppression of Free Radical Levels and Activating Proliferative Processes. Rejuvenation Research, 14(5).

  24. Shields, H. J., Traa, A., & Van Raamsdonk, J. M. (2021). Beneficial and detrimental effects of reactive oxygen species on lifespan: A comprehensive review of comparative and experimental studies. Frontiers in Cell and Developmental Biology, 9, 628157.

  25. University College London. (2025). "Pausing" cell death could be the key to longevity. SciTechDaily.

  26. Ansari, M. A., & Scheff, S. W. (2010). Oxidative stress in the progression of Alzheimer's disease in the frontal cortex. Journal of Neuropathology & Experimental Neurology, 69(2), 155-167.

  27. Ilina, A., et al. (2022). Neuroepigenetic mechanisms of action of ultrashort peptides in Alzheimer’s disease. International Journal of Molecular Sciences, 23(8), 4259.

  28. Wójtowicz, S., et al. (2020). The novel role of PPAR alpha in the brain: Promising target in therapy of Alzheimer's disease and other neurodegenerative disorders. Neurochemical Research, 45(5), 972-988.

  29. Walker, L. C. (2020). Aβ plaques. Free Neuropathology, 1, 31.

  30. Mendzheritskii, A. M., Karantysh, G. V., & Ivonina, K. O. (2012). The effects of administering short peptides before occlusion of the carotid arteries on the behavior and caspase-3 activity in the brain of old rats. Advances in Gerontology, 1, 322-327.

  31. Khavinson, V. K., et al. (2014). Short peptides stimulate serotonin expression in cells of brain cortex. Bulletin of Experimental Biology and Medicine, 157, 77-80.

  32. Cleveland Clinic. (2022). Serotonin. Cleveland Clinic.

  33. Aliferova, V. M., et al. (2014). Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of Cortexin in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 114(4), 41-46.

  34. Liu, E., et al. (2004). Preventing peptide-induced anaphylaxis: Addition of C-terminal amino acids to produce a neutral isoelectric point. Journal of Allergy and Clinical Immunology, 114, 607-613.

  35. De Groot, A. S., et al. (2023). Immunogenicity risk assessment of synthetic peptide drugs and their impurities. Drug Discovery Today, 28(10), 103714.

  36. U.S. Food & Drug Administration. (2016). Prescription requirement under Section 503A of the Federal Food, Drug, and Cosmetic Act; Draft guidance for industry; Availability. FDA.

  37. National Institute for Biological Standards and Control. (n.d.). Peptide handling, dissolution & storage. NIBSC.

  38. Grisham, J. (2014). What is apoptosis? Memorial Sloan Kettering Cancer Center.

  39. Zhou, M., et al. (2019). Caspase-3 regulates the migration, invasion, and metastasis of colon cancer cells. International Journal of Cancer, 143(4), 921-930.